Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-05-05

Clinical Trial Update: A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial update for TriACT, a triple combination antiviral therapy for COVID-19, terminated with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TriACT

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: SARS-CoV Infection, Covid19 | Phase 2 | Status: TERMINATED | Results posted: 2022-05-05